Immunocore (IMCR) Stock Forecast & Price Target $29.54 +0.61 (+2.11%) Closing price 04:00 PM EasternExtended Trading$29.55 +0.01 (+0.03%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immunocore - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 10 Analyst RatingsSell1Hold3Buy6 Based on 10 Wall Street analysts who have issued ratings for Immunocore in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a sell rating, 3 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for IMCR. Consensus Price Target $57.7595.50% Upside According to the 10 analysts' twelve-month price targets for Immunocore, the average price target is $57.75. The highest price target for IMCR is $100.00, while the lowest price target for IMCR is $33.00. The average price target represents a forecasted upside of 95.50% from the current price of $29.54. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for IMCR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Immunocore and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMCR Analyst Ratings Over TimeTypeCurrent Forecast5/20/25 to 5/20/261 Month Ago4/20/25 to 4/20/263 Months Ago2/19/25 to 2/19/261 Year Ago5/20/24 to 5/20/25Strong Buy1 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy5 Buy rating(s)6 Buy rating(s)8 Buy rating(s)6 Buy rating(s)Hold3 Hold rating(s)4 Hold rating(s)3 Hold rating(s)3 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$57.75$60.89$60.40$58.13Forecasted Upside95.50% Upside93.54% Upside82.09% Upside79.45% UpsideConsensus RatingModerate BuyHoldModerate BuyModerate Buy IMCR Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History IMCR Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Immunocore Stock vs. The CompetitionTypeImmunocoreMedical CompaniesBroader MarketConsensus Rating Score 2.60 2.29 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside95.50% Upside1,725.91% Upside16.44% UpsideNews Sentiment RatingPositive NewsSee Recent IMCR NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/7/2026 Zacks ResearchNot Rated UpgradeStrong Sell ➝ Strong-Buy4/21/2026 Weiss RatingsNot Rated Reiterated RatingSell (E+)4/20/2026 HC Wainwright4 of 5 starsPatrick R.Not RatedReiterated RatingBuy$100.00+218.37%3/16/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingClara DongSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$48.00 ➝ $33.00+6.93%2/26/2026 Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGil BlumSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$71.00 ➝ $75.00+133.21%2/19/2026 MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$38.00+16.89%1/7/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael YeeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetSell ➝ Buy$24.00 ➝ $55.00+67.43%11/10/2025 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrew GallerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetEqual Weight$34.00 ➝ $36.00+4.27%10/31/2025 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEva Fortea VerdejoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOverweight$60.00+86.39%9/18/2025 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingPaul JengSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageNeutralForget SpaceX. Buy the company Musk can't replace. (Ad)The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks and insiders have already locked it up. But there is one small, publicly traded company that builds the critical infrastructure SpaceX cannot operate without. Dylan Jovine is releasing the ticker name today at no cost.Get the SpaceX backdoor ticker symbol before the market opens5/27/2025 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Initiated CoverageBuy$65.00+108.60%5/8/2025 OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJeff JonesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$85.00 ➝ $86.00+193.42%4/14/2025 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJessica FyeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$54.00 ➝ $50.00+88.04%9/9/2024 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOverweight8/9/2024 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetOverweight$92.00 ➝ $66.00+74.05%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:27 PM ET. IMCR Forecast - Frequently Asked Questions What is Immunocore's forecast for 2026? According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Immunocore is $57.75, with a high forecast of $100.00 and a low forecast of $33.00. Should I buy or sell Immunocore stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last year. There is currently 1 sell rating, 3 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IMCR shares. Does Immunocore's stock price have much upside? According to analysts, Immunocore's stock has a predicted upside of 95.50% based on their 12-month stock forecasts. Has Immunocore been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Immunocore's stock had 3 downgrades and 1 upgrade by analysts. What analysts cover Immunocore? Immunocore has been rated by research analysts at HC Wainwright, Jefferies Financial Group, Mizuho, Needham & Company LLC, Weiss Ratings, and Zacks Research in the past 90 days. Do Wall Street analysts like Immunocore more than its competitors? Analysts like Immunocore more than other "medical" companies. The consensus rating for Immunocore is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how IMCR compares to other companies. Stock Forecasts and Research Tools Related Companies Centessa Pharmaceuticals Stock Forecast Scholar Rock Stock Forecast Cogent Biosciences Stock Forecast Xenon Pharmaceuticals Stock Forecast Apellis Pharmaceuticals Stock Forecast Grifols Stock Forecast Apogee Therapeutics Stock Forecast CRISPR Therapeutics Stock Forecast Dianthus Therapeutics Stock Forecast Indivior Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Immunocore RecommendationsWall Street ZenZacks ResearchWeiss RatingsHC WainwrightJefferies Financial GroupNeedham & Company LLCMizuhoUBS GroupMorgan StanleyWells Fargo & CompanyGuggenheimDeutsche Bank Aktiengesellschaft This page (NASDAQ:IMCR) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredThe sell discipline that changed my mind after 30 yearsPorter Stansberry spent 30 years ignoring outside investment systems - until he met Emmet Savage in Dublin. Sa...Porter & Company | SponsoredMemorial Day Event: Save 79% on Weiss Ratings Plus!Elon Musk calls it 'mind-blowing.' Fox News calls the scramble for it 'the new arms race.' Chris Graebe, Chief...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
